RPG Life Sciences Partners Archerchem for Naprosyn ES Launch in India
RPG Life Sciences has partnered with Archerchem Healthcare to launch Naprosyn ES, a combination of Naproxen and Esomeprazole, in India. RPG LS will market and distribute the product exclusively, while Archerchem will be the exclusive supplier. This launch aims to provide safer long-term pain management and improve patient compliance.
The launch of a new combination drug addresses an unmet medical need and expands the company's product portfolio, potentially leading to revenue growth and improved market presence.
The announcement details a new product launch through a strategic partnership, which is expected to benefit patients and strengthen the company's market position.
RPG Life Sciences (RPG LS) has announced a strategic partnership with Archerchem Healthcare to launch Naproxen and Esomeprazole combination, branded as Naprosyn ES, for the first time in India. This collaboration strengthens their existing business relationship, with Archerchem serving as the exclusive supplier and RPG LS handling exclusive marketing and distribution across the country.
Naprosyn ES is a novel formulation designed to provide effective anti-inflammatory relief coupled with gastro-protection. It aims to address a significant unmet need for patients requiring long-term Nonsteroidal Anti-Inflammatory Drug (NSAID) therapy, especially those at risk of gastrointestinal complications. The differentiated formulation is expected to enhance patient compliance and facilitate safer long-term pain management, particularly for elderly and gastro-sensitive individuals.
Ashok Nair, Managing Director of RPG Life Sciences, highlighted the company's patient-centric approach and R&D-driven strategy, emphasizing the trust in the Naprosyn brand. Anil Dhedia, Chairman & Managing Director of Archerchem Healthcare, noted the partnership as a testament to Archerchem's expertise in developing complex formulations and delivering incremental innovation.
RPG Life Sciences plans to leverage the established Naprosyn brand legacy and its extensive network of doctors and a pan-India distribution system to drive the product's reach. This launch aligns with RPG LS's strategic focus on expanding its differentiated portfolio in chronic therapy segments. Naprosyn ES is now available across India.
What to do with a filing like this
RPG Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by RPG Life Sciences Limited. Read the original for the full detail.